UCB Presents Positive Data on Doxecitine and Doxribtimine for Thymidine Kinase 2 Deficiency

UCB shared encouraging results from its research into doxecitine and doxribtimine. These investigational therapies show promise in treating thymidine kinase 2 deficiency, a rare genetic disorder. The positive data presented at the MDA 2025 conference indicate that these drugs may offer significant therapeutic benefits for patients with this condition. Further studies are needed, but this positive initial data provides hope for a new treatment. This is particularly significant given the unmet medical need in this rare disease area. The findings could lead to the development of a new treatment option for patients and families who currently face limited alternatives.